Toxicity of antiretroviral agents.
Struble
K A
KA
U.S. Food and Drug Administration, Rockville, Maryland 20857, USA.
Pratt
R D
RD
Gitterman
S R
SR
D019380:Anti-HIV Agents / Q000009:adverse effects*; D016049:Didanosine / Q000009:adverse effects; D015658:HIV Infections / Q000209:etiology / Q000517:prevention & control*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006282:Health Personnel; D006801:Humans; D019469:Indinavir / Q000009:adverse effects; D019259:Lamivudine / Q000009:adverse effects; D016273:Occupational Exposure / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D019438:Ritonavir / Q000009:adverse effects; D019258:Saquinavir / Q000009:adverse effects; D018119:Stavudine / Q000009:adverse effects; D016047:Zalcitabine / Q000009:adverse effects; D015215:Zidovudine / Q000009:adverse effects
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine; D018119:Stavudine; D016049:Didanosine; D019258:Saquinavir; D019438:Ritonavir